Vistin Pharma ASA (FRA:VP4)
Germany · Delayed Price · Currency is EUR 1.765
-0.065 (-3.55%)
At close: Jan 30, 2026
Vistin Pharma ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 454.83 | 429.09 | 435.39 | 287.68 | 275.81 | 253.16 |
Other Revenue | 0.41 | 0.41 | 2.94 | 17.18 | 2.81 | 0.75 |
| 455.25 | 429.5 | 438.33 | 304.85 | 278.62 | 253.91 | |
Revenue Growth (YoY) | 6.73% | -2.01% | 43.78% | 9.41% | 9.74% | 11.30% |
Cost of Revenue | 152.81 | 149.97 | 176.64 | 138.06 | 96.1 | 73.29 |
Gross Profit | 302.44 | 279.53 | 261.68 | 166.79 | 182.53 | 180.62 |
Selling, General & Admin | 87.03 | 81.72 | 81.84 | 69.73 | 64.96 | 64.34 |
Other Operating Expenses | 99.16 | 93.49 | 93.9 | 90.88 | 73.71 | 61.1 |
Operating Expenses | 207.76 | 194.24 | 193.09 | 172.88 | 149.28 | 135.06 |
Operating Income | 94.68 | 85.3 | 68.6 | -6.1 | 33.25 | 45.56 |
Interest Expense | - | -2.34 | -2.27 | -2.14 | -0.36 | -0.82 |
Interest & Investment Income | 8.41 | 0.51 | 0.22 | 0.03 | 0.27 | 1.72 |
Currency Exchange Gain (Loss) | -3.05 | -3.05 | -7.92 | 2.51 | -1.13 | -23.84 |
Other Non Operating Income (Expenses) | 0.04 | 0.04 | -0.11 | -0.31 | -0.03 | -146.89 |
EBT Excluding Unusual Items | 100.08 | 80.45 | 58.52 | -6.01 | 32 | -124.27 |
Pretax Income | 100.08 | 80.45 | 58.52 | -6.01 | 32 | -124.27 |
Income Tax Expense | 22.02 | 17.7 | 12.92 | -1.29 | 7.13 | -27.32 |
Earnings From Continuing Operations | 78.06 | 62.75 | 45.6 | -4.72 | 24.87 | -96.96 |
Net Income | 78.06 | 62.75 | 45.6 | -4.72 | 24.87 | -96.96 |
Net Income to Common | 78.06 | 62.75 | 45.6 | -4.72 | 24.87 | -96.96 |
Net Income Growth | 27.20% | 37.62% | - | - | - | - |
Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | 44 |
Shares Outstanding (Diluted) | 44 | 44 | 44 | 44 | 44 | 44 |
EPS (Basic) | 1.76 | 1.42 | 1.03 | -0.11 | 0.56 | -2.19 |
EPS (Diluted) | 1.76 | 1.42 | 1.03 | -0.11 | 0.56 | -2.19 |
EPS Growth | 27.20% | 37.62% | - | - | - | - |
Free Cash Flow | 64.9 | 67.05 | 72.69 | -74.8 | -18.26 | -198.83 |
Free Cash Flow Per Share | 1.46 | 1.51 | 1.64 | -1.69 | -0.41 | -4.48 |
Dividend Per Share | 1.250 | 1.250 | 1.000 | 0.750 | 0.750 | 0.500 |
Dividend Growth | 25.00% | 25.00% | 33.33% | - | 50.00% | -50.00% |
Gross Margin | 66.43% | 65.08% | 59.70% | 54.71% | 65.51% | 71.14% |
Operating Margin | 20.80% | 19.86% | 15.65% | -2.00% | 11.93% | 17.94% |
Profit Margin | 17.15% | 14.61% | 10.40% | -1.55% | 8.92% | -38.19% |
Free Cash Flow Margin | 14.26% | 15.61% | 16.58% | -24.54% | -6.55% | -78.31% |
EBITDA | 115.2 | 103.27 | 84.89 | 5.33 | 42.79 | 54.28 |
EBITDA Margin | 25.30% | 24.04% | 19.37% | 1.75% | 15.36% | 21.38% |
D&A For EBITDA | 20.51 | 17.97 | 16.3 | 11.43 | 9.54 | 8.73 |
EBIT | 94.68 | 85.3 | 68.6 | -6.1 | 33.25 | 45.56 |
EBIT Margin | 20.80% | 19.86% | 15.65% | -2.00% | 11.93% | 17.94% |
Effective Tax Rate | 22.00% | 22.00% | 22.08% | - | 22.28% | - |
Revenue as Reported | 429.5 | 429.5 | 438.33 | 304.85 | 278.62 | 253.91 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.